Investor Relations

Investor Relations

Corporate Overview

Pulmonx® Corporation (NASDAQ: LUNG) is a global leader in minimally invasive treatments for lung disease. The Pulmonx solution, which is comprised of the Zephyr® Endobronchial Valve (Zephyr Valve), the Chartis® Pulmonary Assessment System (Chartis System) and the StratX® Lung Analysis Platform, is designed to treat severe emphysema/COPD patients who, despite medical management, are still profoundly symptomatic. Pulmonx received FDA pre-market approval to commercialize the Zephyr Valve following its designation as a “breakthrough device.” The Zephyr Valve is now commercially available in more than 25 countries, with over 80,000 valves used to treat more than 20,000 patients. For more information, visit

Stock Quote

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Recent Events

Nov 10, 2020 4:30 PM EST
News & Events
Stock Information
SEC Filings
Corporate Governance
Investor Resources